Aligos Therapeutics (ALGS) Competitors $5.63 -0.43 (-7.10%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$5.60 -0.02 (-0.44%) As of 05/21/2025 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALGS vs. NLTX, EPRX, ACRS, ADCT, LRMR, EDIT, GLSI, TARA, SCPH, and LYELShould you be buying Aligos Therapeutics stock or one of its competitors? The main competitors of Aligos Therapeutics include Neoleukin Therapeutics (NLTX), Eupraxia Pharmaceuticals (EPRX), Aclaris Therapeutics (ACRS), ADC Therapeutics (ADCT), Larimar Therapeutics (LRMR), Editas Medicine (EDIT), Greenwich LifeSciences (GLSI), Protara Therapeutics (TARA), scPharmaceuticals (SCPH), and Lyell Immunopharma (LYEL). These companies are all part of the "pharmaceutical products" industry. Aligos Therapeutics vs. Neoleukin Therapeutics Eupraxia Pharmaceuticals Aclaris Therapeutics ADC Therapeutics Larimar Therapeutics Editas Medicine Greenwich LifeSciences Protara Therapeutics scPharmaceuticals Lyell Immunopharma Aligos Therapeutics (NASDAQ:ALGS) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, community ranking, earnings, media sentiment, analyst recommendations and profitability. Which has more volatility & risk, ALGS or NLTX? Aligos Therapeutics has a beta of 2.76, suggesting that its share price is 176% more volatile than the S&P 500. Comparatively, Neoleukin Therapeutics has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500. Do analysts prefer ALGS or NLTX? Aligos Therapeutics currently has a consensus target price of $70.00, suggesting a potential upside of 1,148.44%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Aligos Therapeutics is more favorable than Neoleukin Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aligos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor ALGS or NLTX? In the previous week, Aligos Therapeutics and Aligos Therapeutics both had 2 articles in the media. Neoleukin Therapeutics' average media sentiment score of 0.37 beat Aligos Therapeutics' score of 0.00 indicating that Neoleukin Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aligos Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Neoleukin Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better earnings & valuation, ALGS or NLTX? Neoleukin Therapeutics has lower revenue, but higher earnings than Aligos Therapeutics. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAligos Therapeutics$3.27M10.48-$87.68M-$17.51-0.32Neoleukin TherapeuticsN/AN/A-$57.56M-$3.11-5.96 Do institutionals & insiders have more ownership in ALGS or NLTX? 60.4% of Aligos Therapeutics shares are owned by institutional investors. Comparatively, 52.4% of Neoleukin Therapeutics shares are owned by institutional investors. 8.8% of Aligos Therapeutics shares are owned by insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is ALGS or NLTX more profitable? Neoleukin Therapeutics has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,283.19%. Neoleukin Therapeutics' return on equity of -37.22% beat Aligos Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aligos Therapeutics-1,283.19% -114.34% -64.58% Neoleukin Therapeutics N/A -37.22%-30.91% Does the MarketBeat Community prefer ALGS or NLTX? Neoleukin Therapeutics received 21 more outperform votes than Aligos Therapeutics when rated by MarketBeat users. However, 67.44% of users gave Aligos Therapeutics an outperform vote while only 45.87% of users gave Neoleukin Therapeutics an outperform vote. CompanyUnderperformOutperformAligos TherapeuticsOutperform Votes2967.44% Underperform Votes1432.56% Neoleukin TherapeuticsOutperform Votes5045.87% Underperform Votes5954.13% SummaryAligos Therapeutics beats Neoleukin Therapeutics on 9 of the 16 factors compared between the two stocks. Get Aligos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALGS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALGS vs. The Competition Export to ExcelMetricAligos TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$34.28M$2.92B$5.36B$8.39BDividend YieldN/A1.72%5.22%4.10%P/E Ratio-0.4230.5126.5919.72Price / Sales10.48400.93391.61116.20Price / CashN/A168.6838.2534.62Price / Book0.183.286.794.51Net Income-$87.68M-$72.17M$3.23B$248.18M7 Day Performance0.85%4.32%4.03%1.14%1 Month Performance21.36%7.68%12.22%15.07%1 Year Performance-64.87%-28.08%16.76%6.59% Aligos Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALGSAligos Therapeutics3.422 of 5 stars$5.63-7.1%$70.00+1,143.3%-64.7%$34.42M$3.27M-0.4290Gap DownNLTXNeoleukin TherapeuticsN/A$14.73-1.8%N/A-45.5%$138.43MN/A-4.7490Gap UpHigh Trading VolumeEPRXEupraxia Pharmaceuticals2.2038 of 5 stars$3.86+1.4%$10.50+172.4%+32.3%$138.20MN/A-5.3529Gap UpACRSAclaris Therapeutics2.8661 of 5 stars$1.25-0.8%$10.67+753.3%+9.3%$135.35M$18.72M-2.40100Gap UpADCTADC Therapeutics2.6699 of 5 stars$1.35+5.9%$7.75+476.2%-47.6%$133.39M$70.84M-0.56310News CoverageEarnings ReportAnalyst RevisionLRMRLarimar Therapeutics2.0664 of 5 stars$2.08-1.9%$19.63+843.5%-75.5%$133.18MN/A-1.8130Positive NewsEDITEditas Medicine4.2632 of 5 stars$1.54+6.2%$5.73+271.9%-72.8%$128.91M$32.31M-0.60230Positive NewsGap UpGLSIGreenwich LifeSciences1.1962 of 5 stars$9.58+1.6%$39.00+307.1%-28.1%$127.17MN/A-11.973Earnings ReportTARAProtara Therapeutics2.1923 of 5 stars$3.27+0.9%$20.40+523.9%+10.9%$126.15MN/A-1.1630Positive NewsGap UpSCPHscPharmaceuticals4.1032 of 5 stars$2.48+1.6%$14.00+464.5%-12.7%$124.70M$36.33M-1.3130Analyst RevisionLYELLyell Immunopharma2.9598 of 5 stars$0.42+5.4%$1.00+137.2%-84.3%$124.52M$61,000.00-0.53270Positive News Related Companies and Tools Related Companies Neoleukin Therapeutics Competitors Eupraxia Pharmaceuticals Competitors Aclaris Therapeutics Competitors ADC Therapeutics Competitors Larimar Therapeutics Competitors Editas Medicine Competitors Greenwich LifeSciences Competitors Protara Therapeutics Competitors scPharmaceuticals Competitors Lyell Immunopharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALGS) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersWarning: Prepare to Be Shocked by These PayoutsThere's a strategy out there paying up to 70% on tech stocks like Amazon, Tesla, and Microsoft—stocks that don...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredTrump’s treachery I think Trump’s Treasury Secretary is destroying the stock market on purpose. And no one on Wall Street see...Porter & Company | Sponsored🚨 Nvidia Just Inked a $7B AI Deal—This Could Change EverythingOn Wednesday, Nvidia stock surged—again. Why? Because Saudi Arabia just announced a multi-billion-dollar AI...Timothy Sykes | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aligos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aligos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ALGS Stock Free ALGS Stock Alerts